Boston Scientific Corp. got a boost from Leerink Swann analyst Rick Wise, who upgraded his rating for the Natick, Mass.-based medical devices giant to “outperform.”
The Abbott Park, Ill.-based devices giant said the expansion of the study examining its everolimus-eluting coronary stent opens up the Dual Anti-Platelet Therapy (PDF) trial to more than 2,000 potential subjects.
Sales of Boston Scientific Corp.’s Taxus coronary stent remain well off last year’s pace and have declined significantly over the past two years due to increased competition, according to regulatory filings (PDF) by the Vancouver-based pharmaceutical company that makes the drug used in the stent’s coating.
What a difference a day makes.
Yesterday Boston Scientific Corp. was fielding false claims and Medicare fraud charges.
Boston Scientific Corp. announced plans for a $128 million research & development lab in Galway, Ireland.
The Natick device maker, which already employs about 5,000 in Ireland, said the project will create roughly 45 jobs over five years, the Independent reported. The lab will focus on early-stage development projects.
Abbott Laboratories fired the latest salvo in the long-running stent war, saying it plans to begin selling its Xience Prime coronary device in Europe during the third quarter after winning CE Mark approval from the European Union.
The latest version of the Chicago-based medical device monolith’s drug-eluting Xience platform competes head-to-head with products from Natick-based peer Boston Scientific, Johnson & Johnson and Medtronic Inc.
The federal watchdog agency cleared the device for treatment of coronary vessels as small as 2.25mm in diameter, making it and its Taxus Express Atom cousin the only two drug-eluting stents approved for procedures involving small vessels in the United States.
The Natick-based stents giant is calling its new nickel-titanium alloy stent, designed to treat iliac artery disease, the “next generation” of nitinol device. The stent launched in Europe in April.
Boston Scientific Corp. can’t seem to catch a break.
Despite the publication of results from vairous clinical trials that show the superiority of drug-eluting stents — and, in one study, the superiority of the Natick device goliath’s DES over its competitors’ — its share price took a more than 2 percent dive today.
You’d think after about 20 years, questions about the efficacy of stents would be settled. You’d be wrong.